OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Immunology Immunotherapy is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Chemotherapy: a double-edged sword in cancer treatment	123
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis	107
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma	100
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study	65
Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma	61
Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma	56
Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer	51
Regulatory T cells promote glioma cell stemness through TGF-β–NF-κB–IL6–STAT3 signaling	49
Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab	49
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors	49
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial	46
Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome	44
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer	44
Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers	42
Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer	42
ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas	42
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis	41
CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration	40
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncol	40
LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2	39
Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models	39
In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes	39
TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer	38
Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis	37
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China	37

Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials	36
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression	35
Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis	35
Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions	35
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors	35
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors	35
CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors	33
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma	33
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma	33